Darling Ingredients’ health brand Rousselot receives U.S. Patent for gelatin technology that improves soft gel capsule stability and efficacy
Darling Ingredients’ health brand Rousselot, announced today that it has been granted U.S. Patent and Trademark Office (USPTO) Patent No. US11795489B2, securing its intellectual property rights for StabiCaps™, a specialized gelatin that improves the formulation and stability of soft gel capsules to enhance the release of active ingredients, including medications.
StabiCaps addresses crosslinking, a common challenge in the dissolution of soft gels that results in slower or incomplete release of nutrients or pharmaceutical ingredients contained within the capsule. Crosslinking occurs when soft gels are exposed to specific active compounds or poor storage conditions causing molecular bonds, that limit or prevent dissolution of the capsule, to form within the capsule shell.
In May 2022, the company also received a patent from the European Patent Office (EPO) for StabiCaps for all major European countries.
“StabiCaps is an essential innovation for soft gel manufacturers because gelatin is a primary ingredient,” said Pierre-Albert Thomas, Rousselot Functional Ingredients Director. “With this new patent, soft gel manufacturers in the U.S. can unlock the benefits of StabiCaps gelatin technology to produce high-quality soft gels with longer shelf stability and improved efficacy for customers.”
Soft gels are among preferred dosage formats for numerous benefits, including ease of swallowing and odor- and taste-masking capabilities. The global soft gels market is projected to grow at a compound annual growth rate of 4.3% from 2023 to 2033.1
StabiCaps is part of Rousselot’s broader portfolio of world-class gelatin solutions for the nutra- and pharmaceutical markets, which also include SiMoGel™, an innovative technology that allows for starch-free gummy production.
1Persistence Market Research - https://www.persistencemarketresearch.com/market-research/softgel-capsules-market.asp